Emcure has excellent capabilities in formulation manufacturing with particular strengths to research, develop and supply finished formulations to the most demanding needs of the global markets. Emcure is today one of the largest contract manufacturers of tablets, capsules, liquids, ointments and creams in India and manufactures the key brands for some of the largest MNCs in India. Association with our principals has lasted many years and has grown over time.

Emcure has multiple formulation manufacturing facilities in close proximity to each other and a well established supply chain as well as vendor development systems that have been institutionalised over the years. All of Emcure's facilities are WHO GMP certified and ISO 9001 accredited for systems. These facilities are regularly audited by global audit teams of principals and have repeatedly measured up to their standards.

Emcure’s foray into supplies to the regulated markets commenced with the setting up of a solid dosages facility at Hinjwadi. The Hinjwadi manufacturing facility has approvals from both the UK MHRA and MCC South Africa, while the USFDA certification was received recently for the solid dosages plant.

A new world-class facility for liquid injectables has been set up to cater to the regulated markets. The Small Volume Parenterals facility has independent lines for filling pre-filled syringes, vials and ampoules. This plant has been set up as per standards and guidelines laid down by US FDA.

To cater to the demand of domestic market and emerging markets a new state of the art facility at Bari - Brahmana Jammu, India was created in 2009. This facility manufactures both solid and liquid orals.
Facility has received regulatory approvals from Local drug authority, WHO - GMP and also accreditations from various Health Authorities from Emerging Markets.

Emcure is building its pipeline of Chiral and achiral APIs. Our API research team constantly seeks to cross the frontiers in developing non-infringing routes for APIs in therapeutic segments like cardiovascular diseases and haematinics. API R&D infrastructure comprises process development laboratories, complete analytical equipment, microbiological facilities, kg scale facilities and pilot plant for scale up and commercial manufacture.

Emcure has an R&D cum pilot scale facility at Pune which houses facilities for design, synthesis and scale up / manufacture of API intermediates and APIs.

Alkylation, acylation, nitration, chloro-sulfonation, hydrogenation, oxidation, reduction, cryogenic reactions, optical resolution, asymmetric synthesis, high temperature reactions and esterification are routinely carried out at this plant by a team of experienced scientists. The focus is on developing niche APIs and Chiral drugs in the cardiovascular and haematinics segments. To cater to the growing demand, a new world class, cGMP commercial API manufacturing facility at Kurkumbh (70 km from Pune) is being set up. This state-of-the-art facility is spread over 15 acres with independent manufacturing blocks being set up in a phased manner to cater to a wide range of APIs. This plant has been designed to comply with global quality requirements.

Emcure has ventured into the field of Biotechnology and is developing a range of recombinant human bio-generics. Emcure has set up a world class facility capable of handling mammalian and bacteria/ yeast based cell lines along with facilities for upstream and downstream processing of biogenerics. Work is in progress to add value to the bio-generics through technologies such as PEGyllation.

Final formulation of the bio-generics will be carried out at Emcure’s injectable facility with the option of offering the finished product either as prefilled syringes, vials or ampoules.